WO2003010542A1 - Diagnostics du cancer - Google Patents

Diagnostics du cancer Download PDF

Info

Publication number
WO2003010542A1
WO2003010542A1 PCT/JP2002/007547 JP0207547W WO03010542A1 WO 2003010542 A1 WO2003010542 A1 WO 2003010542A1 JP 0207547 W JP0207547 W JP 0207547W WO 03010542 A1 WO03010542 A1 WO 03010542A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
fluorescent substance
peptide
tissue slice
wavelength
Prior art date
Application number
PCT/JP2002/007547
Other languages
English (en)
French (fr)
Inventor
Hisae Niki
Toshiaki Tagawa
Saiko Hosokawa
Original Assignee
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation filed Critical Mitsubishi Pharma Corporation
Priority to JP2003515861A priority Critical patent/JPWO2003010542A1/ja
Priority to CA002454515A priority patent/CA2454515A1/en
Priority to EP02751682A priority patent/EP1411357A4/en
Priority to US10/483,994 priority patent/US20050032132A1/en
Publication of WO2003010542A1 publication Critical patent/WO2003010542A1/ja

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PCT/JP2002/007547 2001-07-25 2002-07-25 Diagnostics du cancer WO2003010542A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003515861A JPWO2003010542A1 (ja) 2001-07-25 2002-07-25 癌診断薬
CA002454515A CA2454515A1 (en) 2001-07-25 2002-07-25 Cancer diagnostics
EP02751682A EP1411357A4 (en) 2001-07-25 2002-07-25 CANCER DIAGNOSTICS
US10/483,994 US20050032132A1 (en) 2001-07-25 2002-07-25 Cancer diagnostics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001224054 2001-07-25
JP2001-224054 2001-07-25

Publications (1)

Publication Number Publication Date
WO2003010542A1 true WO2003010542A1 (fr) 2003-02-06

Family

ID=19057287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007547 WO2003010542A1 (fr) 2001-07-25 2002-07-25 Diagnostics du cancer

Country Status (5)

Country Link
US (1) US20050032132A1 (ja)
EP (1) EP1411357A4 (ja)
JP (1) JPWO2003010542A1 (ja)
CA (1) CA2454515A1 (ja)
WO (1) WO2003010542A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012029752A1 (ja) * 2010-08-31 2012-03-08 コニカミノルタエムジー株式会社 生体物質検出方法
JP2012208106A (ja) * 2011-03-17 2012-10-25 Konica Minolta Medical & Graphic Inc 病理診断情報生成方法及び病理診断情報生成システム
JP2013088296A (ja) * 2011-10-19 2013-05-13 Konica Minolta Medical & Graphic Inc 組織評価方法
JP2013114233A (ja) * 2011-11-30 2013-06-10 Olympus Corp 画像処理装置、顕微鏡システム、画像処理方法、及び画像処理プログラム
JPWO2013035688A1 (ja) * 2011-09-09 2015-03-23 コニカミノルタ株式会社 組織染色方法
US11378517B2 (en) 2010-08-31 2022-07-05 Konica Minolta, Inc. Biological substance detection method

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030602A1 (ja) * 2004-09-16 2006-03-23 Mitsubishi Pharma Corporation 卵巣癌の診断および／または治療薬
WO2007138143A2 (es) * 2006-05-29 2007-12-06 Consejo Superior De Investigaciones Cientificas Anticuerpos monoclonales anti-colina quinasa alfa y su uso en técnicas analíticas, de diagnóstico del cáncer y en la preparación de medicamentos
US11293870B2 (en) * 2013-03-29 2022-04-05 Mie University Vital stain
WO2016029208A1 (en) * 2014-08-22 2016-02-25 University Of South Florida System and method for automated stereology of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01147368A (ja) * 1987-10-21 1989-06-09 Becton Dickinson & Co 蛍光標識としてのペリジニン−クロロフィル複合体
JPH03200064A (ja) * 1989-12-28 1991-09-02 Kosumitsuku:Kk 悪性腫瘍に対する抗体、及びこの抗体を用いた悪性腫瘍の判別方法
JPH06113831A (ja) * 1992-04-08 1994-04-26 Dev Center For Biotechnol ハイブリドーマおよびその抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660001B2 (en) * 1990-10-25 1995-06-08 Trustees Of Columbia University In The City Of New York, The Development of DNA probes and immunological reagents of human tumor associated antigens
US6159751A (en) * 1990-10-25 2000-12-12 The Trustees Of Columbia University In The City Of New York Development of DNA probes and immunological reagents of human tumor associated antigens
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
DE69227623T2 (de) * 1992-04-10 1999-05-20 Erland Uppsala Hanas Verfahren zum Nachweis einer CMV-Infektion
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO2003009870A1 (fr) * 2001-07-25 2003-02-06 Mitsubishi Pharma Corporation Remedes traitant le cancer du sein
US7771718B2 (en) * 2002-04-22 2010-08-10 Fred Hutchinson Cancer Research Center Soluble MIC polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01147368A (ja) * 1987-10-21 1989-06-09 Becton Dickinson & Co 蛍光標識としてのペリジニン−クロロフィル複合体
JPH03200064A (ja) * 1989-12-28 1991-09-02 Kosumitsuku:Kk 悪性腫瘍に対する抗体、及びこの抗体を用いた悪性腫瘍の判別方法
JPH06113831A (ja) * 1992-04-08 1994-04-26 Dev Center For Biotechnol ハイブリドーマおよびその抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1411357A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012029752A1 (ja) * 2010-08-31 2012-03-08 コニカミノルタエムジー株式会社 生体物質検出方法
US9976959B2 (en) 2010-08-31 2018-05-22 Konica Minolta Medical & Graphic, Inc. Biological substance detection method using florescent dye-containing particle
US11378517B2 (en) 2010-08-31 2022-07-05 Konica Minolta, Inc. Biological substance detection method
JP2012208106A (ja) * 2011-03-17 2012-10-25 Konica Minolta Medical & Graphic Inc 病理診断情報生成方法及び病理診断情報生成システム
JPWO2013035688A1 (ja) * 2011-09-09 2015-03-23 コニカミノルタ株式会社 組織染色方法
US10551378B2 (en) 2011-09-09 2020-02-04 Konica Minolta, Inc. Tissue staining method
US11435348B2 (en) 2011-09-09 2022-09-06 Konica Minolta, Inc. Tissue staining method
JP2013088296A (ja) * 2011-10-19 2013-05-13 Konica Minolta Medical & Graphic Inc 組織評価方法
JP2013114233A (ja) * 2011-11-30 2013-06-10 Olympus Corp 画像処理装置、顕微鏡システム、画像処理方法、及び画像処理プログラム
US9632300B2 (en) 2011-11-30 2017-04-25 Olympus Corporation Image processing apparatus, microscope system, image processing method, and computer-readable recording medium

Also Published As

Publication number Publication date
CA2454515A1 (en) 2003-02-06
EP1411357A1 (en) 2004-04-21
JPWO2003010542A1 (ja) 2004-11-18
US20050032132A1 (en) 2005-02-10
EP1411357A4 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR9917218A (pt) Anticorpos monoclonais, antìgenos, e diagnósticoe terapia de doenças malignas
WO1998042740A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2003010542A1 (fr) Diagnostics du cancer
EP1870466A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
EP2277892A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
WO2003087831A3 (en) Proteins involved in breast cancer
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2000000615A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
ATE349533T1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
WO2004006854A3 (en) Method for identification of biologically active agents
WO2002077176A3 (en) Aberrantly expressed proteins in laser capture microdissected tumors
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
DE602004006396D1 (de) Analyse einer zusammenstellung mit beobachtung
WO2001085949A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
EP3862441A3 (en) Method for the early diagnosis of cancer by means of ddpcr analysis of mirna and protein markers in liquid biopsy
WO2004072295A3 (en) Strokes shift emission spectroscopy for detection of disease and physiological state of specimen
EP2322209A3 (en) Tumor specific oligosaccharide epitopes and use thereof
WO2004113574A3 (en) Methods for disease screening
WO2003000733A3 (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
Sumi et al. The luminance ratio of autofluorescence in a xenograft mouse model is stable through tumor growth stages

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003515861

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2454515

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002751682

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002751682

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10483994

Country of ref document: US